Author: United States. Congress. House. Committee on Veterans' Affairs
Publisher:
Published: 2009
Total Pages: 234
ISBN-13:
DOWNLOAD EBOOK →Author: United States. Congress. House
Publisher:
Published: 2007
Total Pages: 388
ISBN-13:
DOWNLOAD EBOOK →Author: United States. Congress
Publisher:
Published: 2008
Total Pages: 712
ISBN-13:
DOWNLOAD EBOOK →Author: United States. Congress
Publisher:
Published: 2008
Total Pages: 712
ISBN-13:
DOWNLOAD EBOOK →The Congressional Record is the official record of the proceedings and debates of the United States Congress. It is published daily when Congress is in session. The Congressional Record began publication in 1873. Debates for sessions prior to 1873 are recorded in The Debates and Proceedings in the Congress of the United States (1789-1824), the Register of Debates in Congress (1824-1837), and the Congressional Globe (1833-1873)
Author: United States. Congress. House
Publisher:
Published: 2010
Total Pages: 1764
ISBN-13:
DOWNLOAD EBOOK →Some vols. include supplemental journals of "such proceedings of the sessions, as, during the time they were depending, were ordered to be kept secret, and respecting which the injunction of secrecy was afterwards taken off by the order of the House."
Author: United States. Congress
Publisher:
Published: 1919
Total Pages: 1084
ISBN-13:
DOWNLOAD EBOOK →Author: Institute of Medicine
Publisher: National Academies Press
Published: 1992-02-01
Total Pages: 239
ISBN-13: 0309048370
DOWNLOAD EBOOK →Like many other agencies of the federal government, the Food and Drug Administration (FDA) relies extensively on external advisory committees for independent scientific and technical advice. Recognizing that the existing advisory committee system is essentially sound, this volume recommends ways of enhancing the use of these committees in the evaluation of drugs, biological materials, and medical devices; strengthening the agency's management of the system; and increasing the accountability of the system to the public. In doing so, it examines and makes recommendations on such issues as the recruitment of committee members, the FDA's management of financial conflict of interest and intellectual bias among members, and the operations and management of the advisory committee system.